New drug combo targets tough blood cancers in phase 2 trial
NCT ID NCT04496349
Summary
This study is testing two experimental drugs, APG-115 and APG-2575, either alone or together, for adults with T-cell prolymphocytic leukemia (T-PLL) or non-Hodgkin's lymphoma (NHL) that has come back or hasn't responded to prior treatment. The main goals are to find safe doses and see if the treatments help control the cancer. It is for people who have tried at least one other therapy and are not eligible for other known beneficial treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKINS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.